Author:
Assefa Ashenafi,Mohammed Hussein,Anand Anjoli,Abera Adugna,Sime Heven,Minta Anna A.,Tadesse Mekonnen,Tadesse Yehualashet,Girma Samuel,Bekele Worku,Etana Kebede,Alemayehu Bereket Hailegiorgis,Teka Hiwot,Dilu Dereje,Haile Mebrahtom,Solomon Hiwot,Moriarty Leah F.,Zhou Zhiyong,Svigel Samaly Souza,Ezema Bryan,Tasew Geremew,Woyessa Adugna,Hwang Jimee,Murphy Matthew
Abstract
Abstract
Background
Routine monitoring of anti-malarial drugs is recommended for early detection of drug resistance and to inform national malaria treatment guidelines. In Ethiopia, the national treatment guidelines employ a species-specific approach. Artemether-lumefantrine (AL) and chloroquine (CQ) are the first-line schizonticidal treatments for Plasmodium falciparum and Plasmodium vivax, respectively. The National Malaria Control and Elimination Programme in Ethiopia is considering dihydroartemisinin-piperaquine (DHA/PPQ) as an alternative regimen for P. falciparum and P. vivax.
Methods
The study assessed the clinical and parasitological efficacy of AL, CQ, and DHA/PPQ in four arms. Patients over 6 months and less than 18 years of age with uncomplicated malaria mono-infection were recruited and allocated to AL against P. falciparum and CQ against P. vivax. Patients 18 years or older with uncomplicated malaria mono-infection were recruited and randomized to AL or dihydroartemisinin-piperaquine (DHA/PPQ) against P. falciparum and CQ or DHA/PPQ for P. vivax. Patients were followed up for 28 (for CQ and AL) or 42 days (for DHA/PPQ) according to the WHO recommendations. Polymerase chain reaction (PCR)-corrected and uncorrected estimates were analysed by Kaplan Meier survival analysis and per protocol methods.
Results
A total of 379 patients were enroled in four arms (n = 106, AL-P. falciparum; n = 75, DHA/PPQ- P. falciparum; n = 142, CQ-P. vivax; n = 56, DHA/PPQ-P. vivax). High PCR-corrected adequate clinical and parasitological response (ACPR) rates were observed at the primary end points of 28 days for AL and CQ and 42 days for DHA/PPQ. ACPR rates were 100% in AL-Pf (95% CI: 96–100), 98% in CQ-P. vivax (95% CI: 95–100) at 28 days, and 100% in the DHA/PPQ arms for both P. falciparum and P. vivax at 42 days. For secondary endpoints, by day three 99% of AL-P. falciparum patients (n = 101) cleared parasites and 100% were afebrile. For all other arms, 100% of patients cleared parasites and were afebrile by day three. No serious adverse events were reported.
Conclusion
This study demonstrated high therapeutic efficacy for the anti-malarial drugs currently used by the malaria control programme in Ethiopia and provides information on the efficacy of DHA/PPQ for the treatment of P. falciparum and P. vivax as an alternative option.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference51 articles.
1. WHO. World malaria report 2021. Geneva, World Health Organization, 2021. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021.
2. Ministry of Health Federal Democratic Republic of Ethiopia. Ethiopian Malaria Review Document. Addis Ababa, Ethiopia; 2020.
3. Ministry of Health Federal Democratic Republic of Ethiopia. National Malaria Elimination Roadmap. National Malaria prevention, control and elimination programme; Disease Prevention and Control Directorate; 2016.
4. WHO. Guideline for the treatment of malaria. Geneva, World Health Organization, 2015.
5. Ministry of Health Federal Democratic Republic of Ethiopia. Malaria diagnosis and treatment guidelines for health workers in Ethiopia. Addis Ababa; 2004.